Heidi Capozzi previously served as chief people officer for McDonald’s.
CVS Health announced that Heidi Capozzi will serve as its new chief people officer.1 Prior to joining CVS Health, Capozzi was the chief people officer at McDonald’s and before that she worked at Boeing.
In a press release, Capozzi said, “I am excited to join CVS Health and be part of a team whose strategy is bold and necessary: redefining how health care is delivered in this country. I admire CVS Health for its leadership in imagining and delivering a personalized health care experience, and I am proud to join a company that is truly colleague and customer focused with a mission dedicated to improving health for everyone."
In the same press release, CVS Health president and CEO Karen S. Lynch said, “Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and advancing a winning culture. From nimble startups to established brands, Heidi has consistently applied her expertise to championing talent and we look forward to her being a part of our leadership team."
CVS Health also recently announced that it had provided $525,000 in Health Zones funding to Central California Food Bank’s (CCFB) City Center Initiative.2
In a press release, CVS Health senior vice president of corporate social responsibility and chief sustainability officer Sheryl Burke said, “When people have access to supportive services, it puts them in a better position to take care of their health and well-being. Our Health Zones organizations in Fresno share our vision of improving health outcomes locally. We believe that by working together and integrating our other community-based efforts through programs like Project Health, we will make a meaningful impact and improve community health here in Fresno."
Central California Food Bank co-CEO Kym Dildine added, “Through this collaborative, the CVS Health Foundation is helping the incredible partners at City Center leverage food and nutrition to connect neighbors to a wide array of community supports that will improve overall health and well-being.”
Also in August, CVS Health announced a new environmental health initiative for people impacted by extreme weather events, such as deadly heat waves or powerful storms, both of which are becoming more common occurrences in the United States.3
In a press release, practicing physician and chief clinical innovation officer at CVS Caremark Dr. Dan Knecht said, “Extreme heat kills more Americans each year than all other weather events combined. In addition to fatalities driven by heat strokes, extreme heat can worsen chronic conditions such as cardiovascular disease, asthma and chronic obstructive pulmonary disease. Most heat-related deaths are preventable with outreach and intervention. We are proud to introduce a new capability that advances our efforts to find innovative ways to deliver personalized health care to consumers."
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.